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Abstract 
Background: Numerous oral anticancer chemotherapies are available. Non‑adherence or over‑adherence to these 
chemotherapies can lead to lowered efficacy and increased risk of adverse events. The objective of this study was to 
identify patients’ adherence profiles using a qualitative–quantitative method.
Methods: A capecitabine treatment was initiated for 38 patients with advanced breast or colorectal cancer. At inclu‑
sion, information on patients’ beliefs was reported using a questionnaire. Later, Information on patients’ relation to 
treatment was obtained from a sub‑group during an interview with a sociologist. Questionnaires were analyzed using 
Multiple Classification Analysis to cluster patients. Treatment adherence was evaluated by an electronic medication 
event monitoring systems (MEMS caps) and then correlated with patient clusters. Interviews were analyzed to com‑
plete and explain results.
Results: 38 patients were enrolled between 2008 and 2011 and completed the questionnaire. Twenty had adher‑
ence measured with MEMS caps all along treatment. Between 4 and 6 months after inclusion, 16 patients were inter‑
viewed. Patient profile B (retired, with a regular life, surrounded by a relative’s attention to drug adherence, with a low 
educational level) was statistically associated with adequate adherence (p = 0.049). A tendency for lower adherence 
was observed among more highly educated patients with an irregular, active life (NS). All patients taking capecitabine 
demonstrated a risk of over‑adherence, potentiating side effects.
Conclusions: These encouraging primary results suggest that further studies should be undertaken and that educa‑
tional programs tailored to patient profiles should be evaluated to enhance adherence for those who need it and to 
empower all patients to manage treatment side effects.
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Background
Oral anticancer therapy is being increasingly used every 
year, in particular cytotoxic agents, and more recent 
targeted therapies, are often administered orally. The 
main advantages of oral administration are the fewer 
hospitalisations and the autonomy gained by patients. 
However, these advantages can be compromised since 
the patient has to be responsible for the ambulatory 
administration and monitoring of these drugs. This 
raises two areas of potential concern: the patient’s 
adherence and the occurrence of unknown side effects. 
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Capecitabine is a fluorouracil (5 FU) prodrug and is 
prescribed orally for the treatment of advanced and 
metastatic breast, colorectal and gastric cancers. Sev-
eral studies have reported patient adherence rates for 
capecitabine that vary from 58 to 100%, mainly depend-
ant on the measurement method [1–11]. In most stud-
ies, non-adherence rate remains at about 20–25% [2, 3, 
5, 7, 11]. The reasons for non-adherence can be grouped 
under three main themes [12]: Personal factors (belief in 
the treatment, emotional state); treatment factors (com-
plexity of treatment, side effects, costs) and healthcare 
provider-related factors (relationship with healthcare 
professionals, prescribing practices). Few factors have 
been identified to explain non-adherence with capecit-
abine: the number of co-medications, and the number 
of side effects [3, 9, 10, 13]. Adherence with capecit-
abine is relatively high compared with other oral cancer 
chemotherapies [14]. It has been suggested that there is 
only one specific group of patients who are non-adher-
ent and that adherence-enhancing intervention should 
be targeted to this group only [7, 9, 13]. The difficulty is 
to be able to identify them early and propose the inter-
ventions to them.
The second area of concern for oral chemotherapy is 
the monitoring of side effects. Capecitabine is respon-
sible for gastrointestinal and dermatologic side effects 
that can lead to life-threatening toxicity, which can be 
resolve by temporarily interrupting treatment or modi-
fying the dose. However, serious side effects still occur 
with capecitabine [15] and these are often related to 
over-adherence since, when side effects occur, there 
is no medical surveillance or management of doses, 
the patients continue to take the drug [16, 17]. This 
over-adherence has been observed, particularly, with 
capecitabine [2, 3, 6, 8, 18]. There is, therefore a need 
to develop interventions that can enable quick recog-
nition of these side effects and their timely, adequate 
management.
The objective of the OCTO study (Observance à une 
ChimioThérapie Orale—Adherence to oral chemother-
apy) was to model adherence of ambulatory patients 
treated with capecitabine. An ancillary study (OCTO-
quali) within the main OCTO study was conducted 
assuming that there were profiles for patients to deter-
mine their non-adherence or over-adherence. The iden-
tification of these profiles would allow early tailored, 
patient education programmes for the adequate admin-
istration and monitoring of their care to be proposed to 
the patients.
The main objective of the OCTOquali study was to 




The OCTOquali study was a prospective monocenter 
cohort study that recruited patients initiating an oral 
capecitabine treatment between November 2008 and 
September 2011. The patients answered a questionnaire 
at inclusion and a sub-group of patients was interviewed 
4–6  months after the inclusion in the study to explore 
their beliefs and behavior related to their treatment. 
These results were analyzed to identify sociological pro-
files among the patients and compare these profiles with 
the patients’ adherence data.
Participants
Patients were recruited in the medical oncology depart-
ment at the Lyon-Sud university hospital of Lyon 
(France). Consecutive adults with colorectal cancer at a 
resected or metastatic stage or breast cancer at a locally 
advanced or metastatic stage, with an indication for an 
ambulatory capecitabine treatment, were screened by the 
oncologists and recruited for the study. Written informed 
consent was obtained from each participant. The study 
was approved by Lyon’s South-East ethical committee 
number 4 (approval number 2008-004097-41).
Setting
Patients were planned to be followed during six treat-
ment cycles. The treatment dose was based on their body 
mass index (BMI), and prescribed as a combination of 
150 and 500 mg tablets. Treatment was taken as morn-
ing and evening doses, at exactly 12  h intervals, within 
30  min after a meal. Tablets could not be split to help 
swallowing. A treatment cycle was 14 days of treatment 
followed by a ‘rest’ week. Half the patients (N = 20) were 
given a bottle of capecitabine with a MEMS cap (Medica-
tion Electronic Monitoring Systems, Aardex), to measure 
their adherence electronically. At inclusion, the patients 
completed an initial questionnaire exploring socio-eco-
nomic characteristics and beliefs about their new oral 
chemotherapy, including self-predicted adherence. 4 to 
6  month after inclusion, the patients were proposed a 
semi-structured interview, conducted by a sociologist to 
evaluate their representations and behavioral adaptations 
made since initiating capecitabine treatment.
Measure of adherence
Adherence was measured during all treatment intake (at 
most 6 cycles) using the timing of each opening of the 
bottle with MEMS caps for 20 patients: This was used to 
define three types of adherence. Patients with an open-
ing time variability of >1 h standard deviation were con-
sidered to have poor adherence, those with an opening 
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time variability of <15 min were considered to have high 
adherence and patients with a variability between were 
considered to have adequately adherence. Those cut-offs 
were defined as clinical relevant by a multidisciplinary 
team (two oncologists and one sociologist). Missed doses 
were very rare in this cohort so we did not measured 
adherence this way.
Questionnaire
The questionnaire was constructed by a sociologist, an 
oncologist and a methodologist. The questionnaire was 
tested on five patients and modified to improve its clar-
ity. The questionnaire, which contained 32 closed ques-
tions answered directly by the patients, focussed on 
their perceptions and expectations (Additional file 1). It 
examined socio-economics conditions, relationship with 
their oncologist, beliefs in treatment efficacy and toxic-
ity, expected adherence, expected changes in behaviour 
related to taking oral chemotherapy.
Interview
Face-to-face interviews were proposed to patients after 
the end of the adherence measurement period (6 cycles 
at most). Patients were randomly recruited for the inter-
views, sampling continuing until data saturation was 
achieved. Interviews were conducted face-to-face with 
a sociologist, lasted at least 1  h and investigated those 
topics : (i) the declared adherence behavior and percep-
tion (ii) the patient understanding of his treatment and 
its management (iii) the place of relatives in treatment 
management (iv) patient’s adverse event declaration and 
management.
See the Additional file  1 for more information on 
“Methods”.
Statistical analysis
Patients’ answers were first analysed descriptively by 
frequencies (percentages) and medians (interquartiles). 
Then they were analysed with a multiple classification 
analysis (MCA) followed by an ascending hierarchical 
classification (AHC), which is an agglomerative hierar-
chical clustering procedure, to statistically and graphi-
cally identify patient clusters.
Adherence categories identified with MEMS caps were 
projected onto a MCA cluster map to graphically identify 
adherence clusters. Patients without adherence meas-
ured with MEMS caps were considered as having missing 
data. Then categories of adherence were compared with 
the whole clusters tendency using univariate analyses. All 
analyses were performed using SAS (version 9.1) with a 
significance threshold of p < 0.05.
The interviews were analysed with socio-analytical 
methods: the different elements of the discourse during 
each interview were connected and then underwent con-
tent analysis.
Clusters identified with the MCA methods were linked 
with the results of the interview analyses, to evaluate the 
concordance of common topics, to explain the MCA 
findings and to describe profiles of interest.
Results
38 patients were included in the OCTOquali study. 20 of 
them were followed by MEMS during all the treatment 
intake, until the first event occurred: either treatment 
discontinuation or the end of the 6 cycles. 16 patients 
were included after the 6 cycles period (with or with-
out treatment), for the interviews, one by one, until data 
saturation was reached. 4 patients refused to conduct the 
interview (Figure 1). The main reason given for not com-
pleting the interview is not being available.
Questionnaire analysis
The average age of the 38 patients who completed the 
questionnaire was 59  years (Table  1). The majority of 
responders included were women (n  =  35; 92%), had 
breast cancer (n = 33; 87%), lived in town (n = 26; 68%). 
Only 32% (n  =  12) still had at least one child living at 
home and 21% (n = 8) had a professional activity.
The patients’ feelings about their treatment, taking 
the treatment and their relationship with their oncolo-
gists are summarized in Table 2. Eight (21%) patients said 
they knew that an alternative treatment, involving intra-
venous administration in hospital, was available. Eleven 
(29%) patients knew perfectly well the dose they had to 
Figure 1 Flow chart of the patients included in the OCTOquali 
cohort.
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take. They said that there were fewer side effects with oral 
treatment and generally ambulatory treatment gave more 
advantages (autonomy, less anxiety, fewer side effects—
all 71%) than disadvantages (the need for rigor of admin-
istration, blood tests and loneliness—all 51%). When 
they were asked about the way their oncologist provided 
information, the patients said they were satisfied; only 3 
(8%) patients said that information related to side effects 
was insufficient. The patients said they wanted to man-
age their new treatment; 13 said they wanted to get more 
information about the treatment, 10 on the internet. The 
majority of patients, 26 (68%), said they wanted to adjust 
their living style to take into consideration the treatment 
administration. Eleven (29%) patients said they could 
miss a dose and 4 that they could miss it voluntarily. Six 
patients said that it was not a problem to miss a dose. 
Sixteen patients said the thought that missing a dose was 
dangerous and 16 said they did not want to answer. If a 
serious side effect occurred, 33 patients (87%) said they 
would continue the treatment, with or without consult-
ing their oncologist.
Clusters identified by the MCA and AHC using 
questionnaires’ responses
Eighteen categorical variables (binary or ordinal) were 
selected for their pertinence to characterize patients: 
socio-demographic variables; relationship to the treat-
ment; relationship with their oncologist and perception 
of treatment adherence. Using these variables the MCA 
generated a 2-dimension map representing the independ-
ent variables (Additional file 1: Figure S1 A). This graphi-
cal representation was used in AHC to define patient 
clusters (Additional file 1: Figure S1 B). The closest obser-
vations were merged to form one cluster, and the process 
reiterated until three clusters appeared (Table 3). Patients 
in cluster A were had a higher educational level and were 
active professionally, with an executive occupation, they 
lived in couples with children and intended to get more 
information about their treatment. Those patients gen-
erally thought that they could miss doses. Cluster B was 
composed mostly of retired people, with a lower educa-
tional level who thought that being non-adherent was 
dangerous. Cluster C was composed of urban patients, 
slightly younger, with a higher educational level than 
patients in cluster B, were on sick leave and had already 
taken oral chemotherapy at home, and they said it was 
not possible to miss a dose.
Adherence results with MEMS records
Among the 20 patients whose adherence was measured 
electronically, adherence was globally estimated as con-
cordant with the prescription since only 23 missed doses 
were recorded for 2,272 predicted doses (99% adher-
ence). Two patients were classified as being less adherent 
(10%), 4 as being highly adherent (20%) and 14 (70%) as 
being adequately adherent, based on the mean inter-dose 
interval, which was estimated to be 12.15  h (Additional 
file 1: Figure S2). The standard deviation for the morning 
dose was estimated to be 1.003 h and 1.06 for the evening 
doses.
Table 1 Patients’ characteristics
Characteristics, N = 38 Patients, n (%) or mean (±sd)
Socio‑demographic characteristics
 Age (years) 58.6 (11)
 Gender
  Women 35 (92.1)
  Men 3 (7.9)
 BMI
  <25.5 10 (26.3)
  25.5–28 18 (47.4)
  >28 10 (26.3)
  Smokers 6 (15.8)
 Residence
  Town 26 (68.4)
  Country 12 (31.6)
 Living conditions
  Alone 11 (28.9)
  As a couple without children 15 (39.5)
  As a couple with children 12 (31.6)
 Educational level
  Primary school 12 (31.6)
  Secondary school 16 (42.1)
  College 8 (21.1)
 Occupation
  In activity 8 (21.1)
  Retired 15 (39.5)
  On sick leave 15 (39.5)
 Actual or former profession
  Artisan or laborer 4 (10.5)
  Intermediate occupation 23 (60.5)
  Executive 8 (21.1)
  Does not apply 3 (7.9)
Disease related characteristics
 Type of cancer
  Breast 33 (86.8)
  Colon 5 (13.2)
 Length of oral chemotherapy
  <3 cycles 13 (34.2)
  ≥3 cycles 25 (65.8)
 Reason for discontinuation
  Toxicity 6 (15.8)
  Disease progression 9 (23.7)
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Cluster profile and adherence behaviour association
When the three adherence categories were projected 
onto the MCACA map (Figure 2), the patients classified 
as being low adherent were graphically located close to 
cluster A. The other two categories of adherence (highly 
adherent and adequate adherent) were located near clus-
ter B. When concordance between clusters and adher-
ence location was tested, cluster B was significantly 
associated with adequate adherence (p = 0.049, Figure 2). 
The associated for the other two were not statistically 
significant.
Comparison of interview results and MCA results: 
confirmation of profiles by a mixed method
Detailed results from the interviews are reported in the 
Additional file 1.
Interviews identified two different profiles based on 
feelings and behaviour related to risk of non-adherence to 
capecitabine (Additional file  1: Table  S1). MCA showed 
that one profile was similar to cluster A and the other 
was similar to both clusters B and C. Patients who had 
active lives, with an active partner and children still at 
home, said that was difficult and constraining to adjust to 
the capecitabine administration. They said their relatives 
were too busy and not available to share their adherence 
issue, leaving the patient alone with this responsibility. 
This loneliness generated anxiety among those patients, 
who were worried about forget to take a dose. These 
patients liked the idea of supervised IV administration in 
a hospital setting, in order to decrease their loneliness by 
being about to talk with healthcare providers. In contrast, 
patients with a regular life, and supportive and available 
relatives said that capecitabine administration was easy 
to organize and they tolerated it well. They shared the 
responsibility of adherence with their partner who helped 
them with the timing of the doses. They said they were 
satisfied and were not anxious about taking oral chemo-
therapy at home.
We were unable to identify profiles of patients for their 
feelings and behaviour related to side effects and over-
adherence. They all had a great expectation in the effi-
cacy of this treatment. This hope surpassed any criticism 
Table 2 Responses to the questionnaire
Responders, N = 38
Cancer treatment
 Already had taken oral chemotherapy 13 (34)
 Knew about the choice between oral/ 
intravenous
8 (21)
 Knew the prescribed dose
  Perfectly well 11 (29)
  Relatively well 22 (58)
  Not well 4 (11)
  Had another treatment for their cancer 10 (26)
  Takes a treatment for side effects related to 
previous cancer treatment
8 (21)
  Takes a treatment for another condition 21 (55)
Feelings related to capecitabine
 Advantages of the oral route, according to the patient
  Autonomy 22 (58)
  Less anxiety 1 (3)
  Fewer side effects 4 (11)
  No advantages 3 (8)
 Disadvantages of the oral route, according to the patient
  The lack of rigour in drug administration 16 (42)
  Blood test 2 (5)
  Loneliness 2 (5)
  No disadvantages 4 (11)
Relationship with the oncologist
 Explanations given by the oncologist about:
  The treatment (organisation, administration) 
were insufficient
1 (3)
  The treatment side effects occurrence were 
insufficient
2 (5)
  Management of the treatment side effects  
were insufficient
3 (8)
 Questions asked to the oncologist about the first prescription  
capecitabine
  Side effects 16 (42)
  Loss of hair 2 (5)
  Efficacy 2 (5)
  Treatment duration 2 (5)
Intention to obtain more information elsewhere 13 (34)
  Other clinician 3 (8)
  Internet 10 (26)
Expected changes in daily life due to capecitabine
 Will have to be organised around the treatment 
administration
26 (69)
 If side effects appear:
  I will stop the treatment 5 (13)
  I will consult a clinician 23 (6A)
  I will continue the treatment whatever 4 (10.5%)
Opinions about adherence
 I think that it is alright to miss a dose 11 (28.9)
 I think that it is alright to stop voluntarily 4 (10.5%)
The numbers are n (%).
Table 2 continued
Responders, N = 38
 I think that missing a dose is dangerous
  Yes 16 (42.1%)
  Did not want to answer the question 16 (42.1%)
  No 6 (15.8%)
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towards capecitabine intake and any side effects occur-
rence. What patients declared to fear at most was dose 
reduction. So face to side effects occurrence, all patients 
developed their own management strategy, in order to 
continue to take the treatment whatever the cost.
Discussion
This study combined complex descriptive statistical 
methods and a sociological approach to identify, explain 
and confirm two adherence profiles: adequately adherent 
(Cluster B) and less adherent (Cluster A). Patients with 
no professional or family obligations, retired, and leading 
a calm and scheduled life, were found to be adequately 
adherent. Adherence was enhanced when the patient had 
a relative who helped them manage their treatment with 
them. These patients had a lower educational level, and 
followed the prescription strictly, for fear they would for-
get a dose. In contrast, patients with an irregular, active 
life, with family and professional obligations were more 
likely to be non-adherent. To keep a schedule when unex-
pected and external events can occur is more difficult. 
These patients experienced loneliness and thought they 
were benefit from having contact with a health profes-
sional, to share the burden of treatment, even that meant 
replacing the oral treatment with intravenous treat-
ment. These patients had a higher educational level and 
were more aware that they could miss a dose of their 
Table 3 description of the three clusters identified by CMA 
and AHC
Clusters, N = 38 P value
Cluster A, N = 16
 Educational level: college 0.0003
 Actual of former profession: executive 0.048
 Reason for discontinuation: disease progression 0.002
 Length of oral chemotherapy ≤3 cycles 0.003
 Intention to get more information elsewhere 0.02
 Thought a dose could be missed during treatment 0.02
 In couple with children 0.049
Cluster B, N = 9
 Occupation: retired <0.0001
 Educational level: primary school 0.0001
 Thought that missing a dose was serious 0.02
 BMI <28 0.042
Cluster C, N = 13
 Educational level: secondary school 0.003
 No discontinuation of protocol 0.004
 Length of oral chemotherapy ≥3 cycles 0.014
 Did not know the prescribed dose well 0.009
 Occupation: sick leave 0.01
 Residence: town 0.03
 Did not think that a dose could be missed during treatment 0.03
 Already had had oral chemotherapy 0.04
 Did not know there was a choice between oral/IV treatment 0.04
Figure 2 Graphical representation of the three clusters identified by the ascending hierarchical classification (AHC), with projection of adherence 
data, obtained for the 20 patients controlled with MEMs caps.
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treatment. This highlights that they are more in need of 
special support to help them manage their treatment.
The results showed that patients under oral capecit-
abine generally adhere to their treatment, with those in 
Cluster A being occasionally non-adherent (Cluster A). 
The occurrence side effects and their management was 
the main issue for all the patients, as they all reported 
having experienced side effects, often quite severe 
(62.5%). The interviews with the sociologist brought out 
the fact that some of these side effects were probably due 
to over-adherence: All the patients had high expectations 
about the efficacy of the capecitabine treatment, and 
were all ready to suffer from any kind of side effect, as 
long as the treatment was not stopped. Thus, they devel-
oped their own to strategies to support the side effects 
and were reluctant to tell their oncologist about them out 
of fear that the treatment would be stopped. This behav-
iour could lead to the side effects becoming more severe 
suggesting that there is a need for tailored support to 
teach patients how to manage the side effects.
Our adherence results are coherent with previously 
published results, i.e. 100% if adherence is defined as the 
number of forgotten tablets [1, 9]. However, when adher-
ence is measured with more specific tools, some patients 
are less adherent than the others (from 40 to 9%, accord-
ing to the studies [1, 2, 9, 10]), so our estimation of 10% of 
non-adherent patients is at the low end of this range, but 
remains consistent.
Some studies that measured over-adherence reported 
this to be between 4 and 44% [2, 6, 8]. In this study 
we did not specifically measure over-adherence, but 
rather investigated patients’ beliefs and behaviour 
related to over-adherence. All patients said they could 
be over-adherent during the interviews, giving a risk of 
over-adherence of 100%. This was supported by their 
misconception about efficacy and side effects reported 
on the questionnaire they completed when they received 
the prescription. Patients systematically overestimated 
the balance between the advantages and disadvantages of 
the oral treatment. They underestimated the risk of side 
effects. Even before starting the treatment, 10.5% of the 
patients said they would not stop treatment if side effects 
occurred. This misgiving increased over time, as was 
observed in the interviews.
Our results showed that there was a good relationship 
between the oncologist and patient; only three patients 
thought the explanations about side effects were insuffi-
cient and only one thought explanations about the treat-
ment were insufficient). In addition, the results showed 
that the patients were motivated to be an active stake-
holder in their care: 34.2% said they were going to find 
more information about the treatment, and 68.4% said 
they were going to organise their daily life around the 
treatment administration. These two positive attitudes 
should be used by healthcare providers to enhance effec-
tive management of treatment administration and moni-
toring by the patients. Patients appeared to be eager to 
become independent about their treatment, so a solution 
could be that their oncologist, that they trust could pro-
pose to them to participate in a programme to help them 
to manage their treatment. A therapeutic education pro-
gramme would seem to be the most relevant interven-
tion in this context. Therapeutic education programmes 
have been shown to be effective in improving treatment 
adherence in patients with non-oncological pathologies 
[19, 20]. It is recommended in the setting of oral capecit-
abine [2, 21] and would empower the patients.
The main limitation of this study is that only 38 
patients were included, with only 20 of them having 
adherence measured with MEMS. This led to a lack of 
power, and to non-significant results for 2 of the 3 pro-
files identified. However, the AHC and MCA analyses 
enabled us to identify an adequate adherence profile. 
Also, graphically there seemed to be a close relation-
ship between low adherence and Cluster A, even if this 
was not statistically significant. What’s more, the con-
tent analyses of the 16 sociologist’s interviews provided 
a wealth of information which was consistent with the 
quantitative results, and confirmed findings. Another 
limitation is the little number of patients with poor and 
high adherence. Thus it is difficult to say if the lack of 
association between those profiles and adherence behav-
ior is due to lack of statistical power or if there is actually 
no association. The last limitation is that there was no 
objective measurement of over adherence and assess-
ment of its relationship to the occurrence and severity 
of side effects, although it seems that this assumption is 
valid based on the patients’ interviews. The results from 
this study have now to be confirmed in a larger study. 
If confirmed, those profiles could be used to develop 
targeted educational interventions, with the objective 
of enhancing adherence and side effects management 
through empowerment of patients.
Conclusion
In conclusion, this study, with a mixed quantitative–
qualitative method, identified an adequate adherence 
profile for oral capecitabine. There also seems to be a 
specific low-adherence profile. The results show that over 
adherence and inadequate management of side effects 
are major issues with oral capecitabine treatment and 
provide some explanation about the patients’ behavior. 
Future studies should confirm those results and evaluate 
the role of tailored therapeutic educational interventions. 
Patients are looking forward for such interventions, 
driven by their healthcare providers.
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